<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ergotamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00696</strong>&#160; (APRD00677)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00696/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00696/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00696.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00696.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00696.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00696.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00696.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00696">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ergotamin</td><td>German</td><td>INN</td></tr><tr><td>Ergotamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Ergotamine</td><td>French</td><td>INN</td></tr><tr><td>Ergotaminum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ergotamine Tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000979/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000979/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000979">DBSALT000979</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Anervan</td><td>Recip</td></tr><tr><td>Antimigraine</td><td>Ta Fong</td></tr><tr><td>Cafergot</td><td>Novartis</td></tr><tr><td>Enxak</td><td>Cazi</td></tr><tr><td>Ergam</td><td>Gedeon Richter</td></tr><tr><td>Ergo-Kranit</td><td>Krewel Meuselbach</td></tr><tr><td>Ergomar</td><td>Rosedale</td></tr><tr><td>Gynaemine</td><td>Sriprasit Dispensary</td></tr><tr><td>Wigrettes</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Avamigran</td><td>Ergotamine and Caffeine</td></tr><tr><td>Beanta</td><td>Ergotamine and Caffeine</td></tr><tr><td>Bellergal Spacetabs</td><td>Belladonna + Ergotamine Tartrate + Phenobarbital</td></tr><tr><td>Bellergal Tab</td><td>Belladonna + Ergotamine (Ergotamine Tartrate) + Phenobarbital</td></tr><tr><td>Cafegotamine</td><td>Ergotamine and Caffeine</td></tr><tr><td>Cafergot Pb Sup</td><td>Belladonna + Caffeine + Ergotamine (Ergotamine Tartrate) + Pentobarbital</td></tr><tr><td>Cafergot Pb Tab</td><td>Belladonna + Caffeine + Ergotamine (Ergotamine Tartrate) + Pentobarbital Sodium</td></tr><tr><td>Cafergot Sup</td><td>Caffeine + Ergotamine Tartrate</td></tr><tr><td>Cafergot Tab</td><td>Caffeine + Ergotamine Tartrate</td></tr><tr><td>Ergodryl Cap</td><td>Caffeine Citrate + Diphenhydramine Hydrochloride + Ergotamine Tartrate</td></tr><tr><td>Ergokoffin</td><td>Ergotamine and Caffeine</td></tr><tr><td>Ergonex</td><td>Ergotamine and Caffeine</td></tr><tr><td>Ericaf</td><td>Ergotamine and Caffeine</td></tr><tr><td>Fencafen</td><td>Ergotamine and Caffeine</td></tr><tr><td>Gravergol Capsules</td><td>Caffeine + Dimenhydrinate + Ergotamine Tartrate</td></tr><tr><td>Megral Tabs</td><td>Caffeine + Cyclizine Hydrochloride + Ergotamine Tartrate</td></tr><tr><td>MIGERGOT</td><td>Caffeine + Ergotamine</td></tr><tr><td>Wigraine Suppositories</td><td>Belladonna + Caffeine + Ergotamine Tartrate</td></tr><tr><td>Wigraine Tab</td><td>Belladonna + Caffeine + Ergotamine Tartrate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>113-15-5</td></tr><tr><th>Weight</th><td>Average: 581.6615<br>Monoisotopic: 581.263819255</td></tr><tr><th>Chemical Formula</th><td>C<sub>33</sub>H<sub>35</sub>N<sub>5</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>XCGSFFUVFURLIX-VFGNJEKYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00696.gif?1265922774">show</a>(12 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Ergolines and Derivatives</td></tr><tr><th>Subclass</th><td>Lysergic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Ergotamines, Dihydroergotamines, and Derivatives</td></tr><tr><th>Alternative parents</th><td>Cyclic Peptides; Indoloquinolines; Benzoquinolines; N-acyl-alpha Amino Acids and Derivatives; Pyrroloquinolines; Quinoline Carboxamides; N-substituted Nicotinamides; Isoindoles and Derivatives; Indoles; Tetrahydropyridines; Oxazolidinediones; Piperazines; Diazinanes; Benzene and Substituted Derivatives; Pyrrolidines; Tertiary Carboxylic Acid Amides; Pyrroles; Secondary Carboxylic Acid Amides; Tertiary Amines; Enolates; Polyamines; Ethers; Carboxylic Acids; Ergoline Derivatives</td></tr><tr><th>Substituents</th><td>cyclic alpha peptide; ergoline skeleton; indoloquinoline; benzoquinoline; n-acyl-alpha amino acid or derivative; quinoline-3-carboxamide; pyrroloquinoline; quinoline; n-substituted nicotinamide; indole or derivative; isoindole or derivative; indole; tetrahydropyridine; oxazolidinedione; 1,4-diazinane; piperazine; benzene; pyrrolidine; pyrrole; tertiary carboxylic acid amide; carboxamide group; tertiary amine; secondary carboxylic acid amide; polyamine; carboxylic acid derivative; ether; carboxylic acid; enolate; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".</td></tr><tr><th>Pharmacodynamics</th><td>Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow.</td></tr><tr><th>Mechanism of action</th><td>Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.</td></tr><tr><th>Absorption</th><td>The bioavailability of sublingually administered ergotamine has not been determined.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Signs of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9311</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9644</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7317</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8678</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7801</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6032</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8205</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7408</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8849</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6759</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9604
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.99
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9840 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8701
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6708
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>3m pharmaceuticals inc</li>
<li>Rosedale therapeutics</li>
<li>Parke davis div warner lambert co</li>
<li>Organon usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.cypressrx.com">Cypress Pharmaceutical Inc.</a></li>
<li><a href="http://www.gwlabs.com">G &amp; W Labs</a></li>
<li>Harvest Pharmaceuticals Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rtherapeutics.com">Rosedale Therapeutics</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Sublingual</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the effect and toxicity of ergotamine.</td></tr><tr><td><a href="/drugs/DB01612">Amyl Nitrite</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the effect and toxicity of ergotamine.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Risk of ergotism and severe ischemia with this association</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01613">Erythrityl Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Amprenavir increases the effect and toxicity of ergot derivative</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00883">Isosorbide Dinitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01020">Isosorbide Mononitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Possible ergotism and severe ischemia with this combination.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB04871">Lorcaserin</a></td><td>Avoid all combinations with any ergot derivative such as ergotamine. The combination can increase the risk of developing serotonin syndrome and/or valvular heart disease.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Possible severe and prolonged vasoconstriction.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir increases the effect and toxicity of ergot derivative</td></tr><tr><td><a href="/drugs/DB00727">Nitroglycerin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB06154">Pentaerythritol Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Contraindicated co-administration</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine.</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine.</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00744">Zileuton</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Caffeine increases absorption.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>